Stock ANEB ANEBULO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Market Closed - Nasdaq
Other stock markets
 21:30:00 20/05/2024 BST 		5-day change 1st Jan Change
2.15 USD -6.52% Intraday chart for Anebulo Pharmaceuticals, Inc. -10.79% -11.16%
02-13 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of Aneb-001 as A Treatment for Acute Cannabinoid Intoxication
CI
Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions
PR
Anebulo Pharmaceuticals, Inc. Appoints Sandra Gardiner as Acting Chief Financial Officer
CI
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
CI
Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
CI
Anebulo Pharmaceuticals : Corporate Presentation November 2022
PU
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022
CI
Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
CI
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022
CI
Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
CI
Anebulo Pharma Sees Topline Mid-Stage Trial Data for Acute Cannabinoid Intoxication July 5
MT
Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANEB Stock
  4. News Anebulo Pharmaceuticals, Inc.
  5. Highlights